Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren-GETUG AFU 26 trial.

被引：0
|
作者：
Colomba, Emeline [1 ]
Flippot, Ronan [2 ]
Dalban, Cecile [3 ]
Negrier, Sylvie [4 ]
Chevreau, Christine [5 ]
Gravis, Gwenaelle [6 ]
Oudard, Stephane [7 ]
Laguerre, Brigitte [8 ]
Barthelemy, Philippe [9 ]
Goupil, Marine Gross [10 ]
Geoffrois, Lionnel [11 ]
Rolland, Frederic [12 ]
Thiery-Vuillemin, Antoine [13 ]
Joly, Florence [14 ]
Ladoire, Sylvain [15 ]
Tantot, Florence [16 ]
Escudier, Bernard [17 ]
Albiges, Laurence [18 ]
机构：
[1] Paris Saclay Univ, Gustave Roussy Canc Campus, Villejuif, France
[2] Gustave Roussy, Dept Med Oncol, Villejuif, France
[3] Ctr Leon Berard, Lyon, France
[4] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[5] IUCT Oncopole Inst Claudius Regaud, Toulouse, France
[6] Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France
[7] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Oncol, Paris, France
[8] Ctr Eugene Marquis, Rennes, France
[9] Inst Cancerol Strasbourg Europe, Strasbourg, France
[10] CHU Bordeaux, Bordeaux, France
[11] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[12] Inst Cancerol Ouest, Dept Med Oncol, St Herblain, France
[13] Univ Hosp Jean Minjoz, Besancon, France
[14] Ctr Francois Baclesse, Dept Med Oncol, Caen, France
[15] Georges Francois Leclerc Canc Ctr, Dijon, France
[16] UNICANCER, Le Kremlin Bicetre, France
[17] Gustave Roussy, Villejuif, France
[18] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.359
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
359
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Safety and efficacy of nivolumab in older patients (pts) with renal cell carcinoma: Results of a sub-group analysis of the GETUG-AFU 26 NIVOREN multicenter phase II study.
    Mourey, Loic
    Dalban, Cecile
    Negrier, Sylvie
    Chevreau, Christine
    Gravis, Gwenaelle
    Thibault, Constance
    Laguerre, Brigitte
    Barthelemy, Philippe
    Borchiellini, Delphine
    Gross-Goupil, Marine
    Geoffrois, Lionnel
    Rolland, Frederic
    Thiery-Vuillemin, Antoine
    Joly, Florence
    Ladoire, Sylvain
    Tantot, Florence
    Escudier, Bernard
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [22] Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
    Rainho, L. T.
    Albiges, L.
    Flippot, R.
    Ajuria, L. Carril
    Dalban, C.
    Escudier, B.
    Naigeon, M.
    Desnoyer, A.
    Teixeira, M.
    Chaput-Gras, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1027 - S1027
  • [23] NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab
    Ajuria, L. Carril
    Naigeon, M.
    Dalban, C.
    Desnoyer, A.
    Rioux-Leclercq, N.
    Sautes-Fridman, C.
    Meylan, M.
    Vano, Y.
    Beuselinck, B.
    Chouaib, S.
    de Oliveira, C.
    Tantot, F.
    Escudier, B.
    Albiges, L.
    Chaput, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S704 - S705
  • [24] The impact of baseline peripheral cytokines on survival in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 Translational study.
    Carril, Lucia
    Naigeon, Marie
    Dalban, Cecile
    Desnoyer, Aude
    Rioux-Leclercq, Nathalie
    Sautes-Fridman, Catherine
    Meylan, Maxime
    Vano, Yann-Alexandre
    Beusenlick, Benoit
    Chouaib, Salem
    de Oliveira, Caroline
    Tantot, Florence
    Escudier, Bernard
    Albiges, Laurence
    Chaput, Nathalie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [25] Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.
    Carril-Ajuria, Lucia
    Naigeon, Marie
    Dalban, Cecile
    Desnoyer, Aude
    Rioux-Leclercq, Nathalie
    Sautes-Fridman, Catherine
    Meylan, Maxime
    Vano, Yann-Alexandre
    Beusenlick, Benoit
    Chouaib, Salem
    de Oliveira, Caroline
    Tantot, Florence
    Flippot, Ronan
    Escudier, Bernard
    Albiges, Laurence
    Chaput, Nathalie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [26] Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome
    Desnoyer, A.
    Larive, A.
    Drubay, D.
    Lanoy, E.
    Vano, Y.
    Rioux-Leclercq, N.
    Chouaib, S.
    Beuselinck, B.
    Tantot, F.
    Escudier, B.
    Chaput, N.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 394 - 394
  • [27] NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)
    Vano, Yann-Alexandre
    Rioux-Leclercq, Nathalie
    Dalban, Cecile
    Sautes-Fridman, Catherine
    Bougouin, Antoine
    Chaput, Nathalie
    Chouaib, Salem
    Beuselinck, Benoit
    Chevreau, Christine
    Gross-Goupil, Marine
    Negrier, Sylvie
    Laguerre, Brigitte
    Borchiellini, Delphine
    Colina-Moreno, Irelka
    Fridman, Wolf-Herman
    Chabaud, Sylvie
    Tantot, Florence
    Monteiro, Janice Barros
    Escudier, Bernard
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
    Motzer, Robert J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce G.
    Kuzel, Timothy M.
    Harrison, Michael R.
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim A.
    Plimack, Elizabeth R.
    Lambert, Alexandre M.
    Waxman, Ian M.
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1430 - 1437
  • [29] RANDOMIZED, DOSE-RANGING PHASE II TRIAL OF NIVOLUMAB FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Motzer, R. J.
    Rini, B. I.
    McDermott, D. F.
    Redman, B.
    Kuzel, T.
    Harrison, M. R.
    Vaishampayan, U. N.
    Drabkin, H.
    George, S.
    Logan, T.
    Margolin, K.
    Plimack, E. R.
    Waxman, I.
    Lambert, A.
    Hammers, H.
    ANNALS OF ONCOLOGY, 2014, 25
  • [30] Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
    Choueiri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard J.
    Kim, Jenny J.
    Kluger, Harriet M.
    Stadler, Walter Michael
    Perez-Gracia, Jose Luis
    McNeel, Douglas G.
    Curti, Brendan D.
    Harrison, Michael Roger
    Plimack, Elizabeth R.
    Appleman, Leonard Joseph
    Fong, Lawrence
    Drake, Charles G.
    Cohen, Lewis J.
    Srivastava, Shivani
    Jure-Kunkel, Maria
    Hong, Quan
    Kurland, John F.
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345